Randomized Trial of Proactive Rapid Genetic Counseling Vs. Usual Care for Newly Diagnosed Breast Cancer Patients

Abstract

Purpose

Breast cancer patients who carry BRCA1/BRCA2 gene mutations may consider bilateral mastectomy. Having bilateral mastectomy at the time of diagnosis not only reduces risk of a contralateral breast cancer, but can eliminate the need for radiation therapy and yield improved reconstruction options. However, most patients do not receive genetic counseling or testing at the time of their diagnosis. In this trial, we tested proactive rapid genetic counseling and testing (RGCT) in newly diagnosed breast cancer patients in order to facilitate pre-surgical genetic counseling and testing.

Methods

Newly diagnosed breast cancer patients at increased risk for carrying a BRCA1/2 mutation were recruited. Of 379 eligible patients who completed a baseline survey, 330 agreed to randomization in a 2:1 ratio to RGCT (n=220) vs. UC (n=108). Primary outcomes were genetic counseling and testing uptake and breast cancer surgical decisions.

Results

RGCT led to higher overall (83.8% vs. 54.6%; p<.0001) and pre-surgical (57.8% vs. 38.7%; p=.001) genetic counseling uptake compared to UC. Despite higher rates of genetic counseling, RGCT did not differ from UC in overall (54.1% vs. 49.1%, p>.10) or pre-surgical (30.6% vs. 27.4%, p>.10) receipt of genetic test results nor did they differ in uptake of bilateral mastectomy (26.6% vs. 21.8%, P>.10).

Conclusions

Although RGCT yielded increased genetic counseling participation, this did not result in increased rates of pre-surgical genetic testing or impact surgical decisions. These data suggest that those patients most likely to opt for genetic testing at the time of diagnosis are being effectively identified by their surgeons.